GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Generation Bio Co (NAS:GBIO) » Definitions » Price-to-Free-Cash-Flow

Generation Bio Co (Generation Bio Co) Price-to-Free-Cash-Flow : N/A (As of Apr. 27, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Generation Bio Co Price-to-Free-Cash-Flow?

As of today (2024-04-27), Generation Bio Co's share price is $2.90. Generation Bio Co's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.95. Hence, Generation Bio Co's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for Generation Bio Co's Price-to-Free-Cash-Flow or its related term are showing as below:

GBIO's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 30.76
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

Generation Bio Co's Free Cash Flow per Share for the three months ended in Dec. 2023 was $-0.45. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $-0.95.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 30.50% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 8.50% per year.

During the past 6 years, Generation Bio Co's highest 3-Year average Free Cash Flow per Share Growth Rate was 30.50% per year. The lowest was -3.20% per year. And the median was 0.10% per year.


Generation Bio Co Price-to-Free-Cash-Flow Historical Data

The historical data trend for Generation Bio Co's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Generation Bio Co Price-to-Free-Cash-Flow Chart

Generation Bio Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial - - - - -

Generation Bio Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Generation Bio Co's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, Generation Bio Co's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Generation Bio Co's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Generation Bio Co's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Generation Bio Co's Price-to-Free-Cash-Flow falls into.



Generation Bio Co Price-to-Free-Cash-Flow Calculation

Generation Bio Co's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=2.90/-0.95
=N/A

Generation Bio Co's Share Price of today is $2.90.
Generation Bio Co's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.95.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Generation Bio Co  (NAS:GBIO) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Generation Bio Co Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Generation Bio Co's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Generation Bio Co (Generation Bio Co) Business Description

Traded in Other Exchanges
N/A
Address
301 Binney Street, Cambridge, MA, USA, 02142
Generation Bio Co is a genetics medicine company that is focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina related diseases.
Executives
Dannielle Appelhans director C/O RUBIUS THERAPEUTICS, INC., 399 BINNEY STREET, SUITE 300, CAMBRIDGE MA 02139
Rowland Charles A Jr director 3338 LANCASHIRE RD, FURLONG PA 18925
Donald William Nicholson director C/O GENERATION BIO CO., 301 BINNEY STREET, SUITE 401, CAMBRIDGE MA 02142
Anthony G. Quinn director C/O AEGLEA BIOTHERAPEUTICS, INC., 901 S. MOPAC EXPWY, STE. 250, AUSTIN TX 78746
Antoinette Paone officer: CHIEF OPERATING OFFICER C/O GENERATION BIO CO., 301 BINNEY STREET, SUITE 401, CAMBRIDGE MA 02142
Yalonda Howze officer: CHIEF LEGAL OFFICER C/O CODIAK BIOSCIENCES, INC., 35 CAMBRIDGEPARK DRIVE, SUITE 500, CAMBRIDGE MA 02140
Phillip Samayoa officer: CHIEF STRATEGY OFFICER C/O GENERATION BIO CO., 301 BINNEY STREET, SUITE 401, CAMBRIDGE MA 02142
Jason P Rhodes director C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Associates X, L.p. 10 percent owner 400 TECHNOLOGY SQ., 10TH FLOOR, CAMBRIDGE MA 02139
Matthew Stanton officer: Chief Scientific Officer C/O GENERATION BIO CO., 301 BINNEY STREET, SUITE 401, CAMBRIDGE MA 02142
Douglas Kerr officer: Chief Development Officer C/O GENERATION BIO CO., 301 BINNEY STREET, SUITE 401, CAMBRIDGE MA 02142
Geoff Mcdonough director, 10 percent owner, officer: See Remarks C/O SURFACE ONCOLOGY, INC., 50 HAMPSHIRE ST., 8TH FLOOR, CAMBRIDGE MA 02139
Tracy Zimmermann officer: Chief Development Officer C/O GENERATION BIO CO., 301 BINNEY STREET, SUITE 401, CAMBRIDGE MA 02142
Cooper Ronald Harold Wilfred director C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE MA 02140
Mark D. Angelino officer: Chief Operating Officer GENERATION BIO CO., 301 BINNEY STREET, SUITE 401, CAMBRIDGE MA 02142